CN111587126A - 组合剂型和用于验证的造影剂毒性最小化方案 - Google Patents

组合剂型和用于验证的造影剂毒性最小化方案 Download PDF

Info

Publication number
CN111587126A
CN111587126A CN201980008252.XA CN201980008252A CN111587126A CN 111587126 A CN111587126 A CN 111587126A CN 201980008252 A CN201980008252 A CN 201980008252A CN 111587126 A CN111587126 A CN 111587126A
Authority
CN
China
Prior art keywords
agent
conjugate
tumor
subject
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980008252.XA
Other languages
English (en)
Chinese (zh)
Inventor
B·赫恩
D·V·圣
S·方丹
G·W·阿什利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prolynx LLC
Original Assignee
Prolynx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prolynx LLC filed Critical Prolynx LLC
Publication of CN111587126A publication Critical patent/CN111587126A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyethers (AREA)
CN201980008252.XA 2018-01-12 2019-01-11 组合剂型和用于验证的造影剂毒性最小化方案 Pending CN111587126A (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201862617095P 2018-01-12 2018-01-12
US62/617,095 2018-01-12
US201862674483P 2018-05-21 2018-05-21
US62/674,483 2018-05-21
US201862700147P 2018-07-18 2018-07-18
US62/700,147 2018-07-18
US201862711423P 2018-07-27 2018-07-27
US201862711421P 2018-07-27 2018-07-27
US62/711,423 2018-07-27
US62/711,421 2018-07-27
US201862716788P 2018-08-09 2018-08-09
US201862716796P 2018-08-09 2018-08-09
US62/716,796 2018-08-09
US62/716,788 2018-08-09
PCT/US2019/013306 WO2019140266A1 (en) 2018-01-12 2019-01-11 Protocol for minimizing toxicity of combination dosages and imaging agent for verification

Publications (1)

Publication Number Publication Date
CN111587126A true CN111587126A (zh) 2020-08-25

Family

ID=67218383

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980008252.XA Pending CN111587126A (zh) 2018-01-12 2019-01-11 组合剂型和用于验证的造影剂毒性最小化方案
CN201980008227.1A Pending CN111587115A (zh) 2018-01-12 2019-01-11 协同癌症治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980008227.1A Pending CN111587115A (zh) 2018-01-12 2019-01-11 协同癌症治疗

Country Status (10)

Country Link
US (4) US20200360545A1 (https=)
EP (2) EP3737383A4 (https=)
JP (3) JP2021510701A (https=)
KR (2) KR20200109345A (https=)
CN (2) CN111587126A (https=)
AU (2) AU2019208024A1 (https=)
CA (2) CA3087628A1 (https=)
MX (3) MX2020007306A (https=)
RU (1) RU2020126774A (https=)
WO (2) WO2019140266A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202116356A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
CN114341162B (zh) 2019-07-10 2025-10-17 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
CN114615978A (zh) * 2019-08-28 2022-06-10 普罗林科斯有限责任公司 Dna损伤响应的偶联抑制剂
CN119213060A (zh) * 2022-04-14 2024-12-27 国立研究开发法人量子科学技术研究开发机构 单一高分子颗粒、活性分子复合物、单一高分子颗粒的制造方法、肿瘤尺寸的计测方法、肿瘤内微细结构的计测方法、生物体组织的成像方法、药物递送体系、造影剂试剂盒
WO2024030998A2 (en) * 2022-08-04 2024-02-08 Prolynx Llc Methods of treating cancer with long-acting topoisomerase i inhibitor
WO2024031005A2 (en) * 2022-08-04 2024-02-08 Prolynx Llc Treating cancer with long-acting topoisomerase i inhibitor

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102711837A (zh) * 2009-11-18 2012-10-03 尼克塔治疗公司 盐形式的多-臂聚合物-药物偶联物
WO2016164578A1 (en) * 2015-04-07 2016-10-13 Memorial Sloan Kettering Cancer Center Nanoparticle immunoconjugates
CN106061483A (zh) * 2013-10-04 2016-10-26 普洛林克斯有限责任公司 Sn‑38的缓释结合物
CN106084005A (zh) * 2016-06-15 2016-11-09 广州军区广州总医院 靶向生长抑素受体的Al18F‑NOTA‑PEG6‑TATE及其制备方法和应用
US20170049767A1 (en) * 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Combination therapy for cancer treatment
CN107050471A (zh) * 2016-12-27 2017-08-18 中国药科大学 基于富勒烯的靶向且具有快速清除特征的显像纳米探针及其制备方法和应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030575A1 (en) 1997-01-08 1998-07-16 Proligo Llc Bioconjugation of macromolecules
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
US20040176270A1 (en) 2002-07-12 2004-09-09 Biomarin Pharmaceutical Inc. Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
EP1580216B1 (en) 2002-10-31 2014-05-14 Nippon Kayaku Kabushiki Kaisha High-molecular weight derivatives of camptothecins
US20040247624A1 (en) 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
ES2629696T3 (es) 2003-09-17 2017-08-14 Nektar Therapeutics Profármacos poliméricos multibrazo
US7462627B2 (en) 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
MX2009002855A (es) 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
WO2009141826A2 (en) * 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
WO2009158668A1 (en) 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
CA2738807A1 (en) 2008-10-21 2010-04-29 Enzon Pharmaceuticals, Inc. Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
JP2012509469A (ja) 2008-11-18 2012-04-19 バクスター・インターナショナル・インコーポレイテッド ポリエチレングリコールサンプルの多分散度および／または分子量分布を決定する方法
WO2010138719A1 (en) 2009-05-28 2010-12-02 Mersana Therapeutics, Inc. Polyal drug conjugates comprising variable rate-releasing linkers
EP2566335B1 (en) 2010-05-05 2016-06-29 Prolynx Llc Controlled release of active compounds from macromolecular conjugates
EP2566334B1 (en) 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
US8703907B2 (en) 2010-05-05 2014-04-22 Prolynx Llc Controlled drug release from dendrimers
TW201215412A (en) 2010-08-30 2012-04-16 Sun Pharma Advanced Res Co Ltd Stable pharmaceutical composition
ES2621857T3 (es) * 2010-11-16 2017-07-05 Array Biopharma, Inc. Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1
WO2012088282A1 (en) 2010-12-21 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds
WO2013049719A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
IN2014MN01819A (https=) * 2012-03-05 2015-07-03 Univ Ramot
TWI486341B (zh) * 2012-05-18 2015-06-01 高雄醫學大學 抑制ａｔｒ與ｆａｎｃｄ２激活之組成物與方法
US9863949B2 (en) * 2013-05-31 2018-01-09 Nektar Therapeutics Method for predicting and evaluating responsiveness to cancer treatment with DNA-damaging chemotherapeutic agents
WO2015066053A2 (en) * 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015118338A1 (en) * 2014-02-07 2015-08-13 Mission Therapeutics Limited Methods for exploiting synthetic lethality and chemo-sensitisation in dna damage response (ddr) pathways
WO2015183876A1 (en) * 2014-05-28 2015-12-03 Memorial Sloan Kettering Cancer Center Bimodal fluorophore-labeled liposomes and associated methods and systems
CA2957721C (en) * 2014-08-13 2021-04-13 The Johns Hopkins University Selective dendrimer delivery to brain tumors
WO2016028636A1 (en) 2014-08-16 2016-02-25 Memorial Sloan Kettering Cancer Center Helical polycarbodiimide polymers and associated imaging, diagnostic, and therapeutic methods
JP6378584B2 (ja) 2014-08-29 2018-08-22 キヤノン株式会社 通信システム、画像処理装置、画像処理装置の制御方法、及びプログラム
US10196412B2 (en) * 2014-12-24 2019-02-05 The Board Of Trustees Of The Leland Stanford Junior University Probe for imaging PARP-1 activity
PL3560924T3 (pl) 2015-04-02 2021-10-11 Merck Patent Gmbh Imidazolonylochinoliny i ich zastosowanie jako inhibitorów kinazy atm
WO2016176462A1 (en) * 2015-04-28 2016-11-03 University Of Central Florida Foundation, Inc. Methods and compositions for theranostic nanoparticles
US10821195B2 (en) 2015-09-10 2020-11-03 Memorial Sloan Kettering Cancer Center Compositions for therapeutics, targeted PET imaging and methods of their use
ES2941968T3 (es) 2015-10-01 2023-05-29 The Whitehead Institute For Biomedical Res Marcaje de anticuerpos
US11154538B2 (en) 2016-02-29 2021-10-26 Synta Pharmaceuticals Corporation Combination therapy for treatment of ovarian cancer
WO2017172678A1 (en) * 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
JP7379795B2 (ja) 2016-04-27 2023-11-15 イミューノメディクス、インコーポレイテッド チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果
CN109069666B (zh) 2016-04-29 2023-04-04 纪念斯隆凯特琳癌症中心 使靶向颗粒穿透、分布和响应于恶性脑肿瘤中的组合物和方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102711837A (zh) * 2009-11-18 2012-10-03 尼克塔治疗公司 盐形式的多-臂聚合物-药物偶联物
CN106061483A (zh) * 2013-10-04 2016-10-26 普洛林克斯有限责任公司 Sn‑38的缓释结合物
WO2016164578A1 (en) * 2015-04-07 2016-10-13 Memorial Sloan Kettering Cancer Center Nanoparticle immunoconjugates
CN107735110A (zh) * 2015-04-07 2018-02-23 纪念斯隆-凯特琳癌症中心 纳米粒子免疫偶联物
US20170049767A1 (en) * 2015-08-20 2017-02-23 Merrimack Pharmaceuticals, Inc. Combination therapy for cancer treatment
CN106084005A (zh) * 2016-06-15 2016-11-09 广州军区广州总医院 靶向生长抑素受体的Al18F‑NOTA‑PEG6‑TATE及其制备方法和应用
CN107050471A (zh) * 2016-12-27 2017-08-18 中国药科大学 基于富勒烯的靶向且具有快速清除特征的显像纳米探针及其制备方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOSES Q. WILKS等: "Imaging PEG-Like Nanoprobes in Tumor, Transient Ischemia, and Inflammatory Disease Models", 《BIOCONJUGATE CHEM》 *
滕再进等: "聚乙二醇前药设计原理与应用研究进展", 《中国药业》 *

Also Published As

Publication number Publication date
MX2020007306A (es) 2020-09-25
KR20200109345A (ko) 2020-09-22
RU2020126774A (ru) 2022-02-14
MX2023005786A (es) 2023-05-29
US20230321286A1 (en) 2023-10-12
JP2024012442A (ja) 2024-01-30
US20200397778A1 (en) 2020-12-24
EP3737416A1 (en) 2020-11-18
JP2021510702A (ja) 2021-04-30
RU2020126853A3 (https=) 2022-02-14
CA3087967A1 (en) 2019-07-18
EP3737383A4 (en) 2021-12-15
RU2020126853A (ru) 2022-02-14
CN111587115A (zh) 2020-08-25
AU2019206623A1 (en) 2020-07-16
AU2019208024A1 (en) 2020-08-13
US11730836B2 (en) 2023-08-22
US20200360545A1 (en) 2020-11-19
WO2019140271A2 (en) 2019-07-18
WO2019140271A3 (en) 2019-08-22
JP2021510701A (ja) 2021-04-30
EP3737416A4 (en) 2022-03-30
EP3737383A2 (en) 2020-11-18
KR20200110377A (ko) 2020-09-23
MX2020007442A (es) 2020-09-14
CA3087628A1 (en) 2019-07-18
US20240082436A1 (en) 2024-03-14
WO2019140266A1 (en) 2019-07-18
JP7703001B2 (ja) 2025-07-04

Similar Documents

Publication Publication Date Title
US20240408251A1 (en) Compositions and methods for targeted particle penetration, distribution, and response in malignant brain tumors
CN111587126A (zh) 组合剂型和用于验证的造影剂毒性最小化方案
US20240042063A1 (en) LINKED AND OTHER pH-TRIGGERED COMPOUNDS
US11931425B2 (en) Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis
ES2977715T3 (es) Inhibidores marcados de antígeno prostático específico de membrana (psma), su uso como agentes formadores de imágenes y agentes farmacéuticos para el tratamiento de cáncer de próstata
Cazzamalli et al. Acetazolamide serves as selective delivery vehicle for dipeptide-linked drugs to renal cell carcinoma
Hoang et al. Block copolymer micelles target Auger electron radiotherapy to the nucleus of HER2-positive breast cancer cells
ES2788865T3 (es) Conjugados farmacéuticos de nanopartículas
Braunová et al. Tumor-targeted micelle-forming block copolymers for overcoming of multidrug resistance
ES2770733T3 (es) Nanopartículas terapéuticas que comprenden un agente terapéutico y procedimientos de fabricación y uso de las mismas
JP2022545636A (ja) 癌の免疫療法のための高性能ペプチド及び可変ナノ粒子
WO2018103660A1 (zh) Vap多肽及其在制备靶向诊疗肿瘤药物中的应用
Zhong et al. Advancements in nanotechnology for the diagnosis and treatment of multiple myeloma
Borgman et al. Biodistribution of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer drug delivery
JP2022514463A (ja) 抗がん剤の送達のための立体錯体
WO2022180126A1 (en) Targeting system with improved uptake
US20250312498A1 (en) Protocol for minimizing toxicity of combination dosages and imaging agent for verification
Chen et al. Multifunctional Nanoprobe Au@ Gd-SiO2-HA-Lyp-1/DOX with Dual-Targeting Functions Derived from HA and LyP-1: Diagnostic and Therapeutic Potential for Tumor Lymphatic Metastasis
US20220118116A1 (en) Adhesive/adsorption switch on nanoparticles to increase tumor uptake and delay tumor clearance
Lalloo Controlled release of the camptothecins from a novel in situ forming hydrogel
Buckway Image-guided therapeutic delivery to solid tumors with HPMA copolymers
BR122024008143A2 (pt) Uso de conjugados de nanopartículas para tratamento de tumor cerebral

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination